CureVac and Arcturus Therapeutics announce broad strategic collaboration
CureVac AG and Arcturus Therapeutics Ltd. announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.
Under the agreement, the companies will collaborate to develop up to four molecular therapy prod ... more
CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics
CureVac AG announced the groundbreaking of its industrial-scale, GMP-compliant production facility at its headquarters in Tübingen, Germany. The novel production facility – called GMP IV – will be able to produce approximately 30 million doses of RNA-based therapeutics per year, and is expe ... more
Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines
Eli Lilly and Company and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive® technology. The companies will use messenger RNA (mRNA) techno ... more